Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells

 Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells

Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells

Shots:

  • Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months
  • BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones on the selection of additional targets
  • In 2016, the companies collaborated to develop & commercialize Ab targeting tumor-associated myeloid cells discovered using BioInvent’s F.I.R.S.T drug discovery platform. The platform allows the discovery of human Ab utilizing n-CoDeR Ab library to identify targets

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioInvent

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post